PARP1 and melanoma: In a recently published case series, we documented the response of three additional melanoma patients with HRD–LOH score ranging from 28–58% to PARP inhibitor therapy after initial failure of immune checkpoint therapy, with a durable response observed in one patient (Zhou JNCCN 2023).